Cytokinetics, Incorporated
Financials
Valuation Metrics
Cytokinetics, Incorporated's Market Cap is $10.38B. At end of 2025 it was $7.75B. Ranked #925 of 3,112 in US market (top 30%), #294 of 1,445 on NASDAQ (top 20%), #43 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $10.38B | US#925/3,112 Sec#43/269 |
| Revenue | $106M | US#2,772/3,112 Sec#124/269 |
| Net Income | $-830M | US—/3,112 Sec—/269 |
| Total Assets | $1.27B | US#2,331/3,112 Sec#81/269 |
| Net Assets | $109M | US#2,870/3,112 Sec#225/269 |
| Employees | 673 | US#1,321/3,112 Sec#43/269 |
| Value | ||
| P/B | 95.61x | US#2,960/3,112 Sec#257/269 |
| P/S | 98.08x | US#2,909/3,112 Sec#181/269 |
| FCF Yield | -5.29% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROA | -65.15% | US#3,017/3,112 Sec#246/269 |
| Op. Margin | -605.06% | US#2,903/3,112 Sec#167/269 |
| Revenue Growth | 1125.78% | US#27/3,112 Sec#12/269 |
| Financial Health | ||
| Debt Ratio | 1934.63% | US#2,899/3,112 Sec#256/269 |
| Total Debt | $1.29B | US#1,348/3,112 Sec#37/269 |
| FCF | $-549M | US#2,842/3,112 Sec#261/269 |
| Cash | $130M | US#2,040/3,112 Sec#157/269 |
| Current Ratio | 4.21x | US#571/3,112 Sec#163/269 |
| Performance | ||
| 1Y Return | 108.34% | US#263/3,112 Sec#71/269 |
| 1M Return | -11.62% | US#2,682/3,112 Sec#184/269 |
| From 52W High | -13.44% | US#1,306/3,112 Sec#77/269 |
| 1Y MDD | -15.01% | US#312/3,112 Sec#10/269 |
| Trading | ||
| Volume | 1,920,519 shares | US#919/3,112 Sec#83/269 |
| Trading Value | $146M | US#672/3,112 Sec#41/269 |
| Per Share | ||
| EPS | $-6.43 | US—/3,112 Sec—/269 |
Company Info
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.